This is the text extract for Provisional agreement with Pacific Pharmaceuticals for the listing of various pharmaceuticals, browse documents here.
20 November 2007 To all interested parties
Consultation on provisional agreement with Pacific Pharmaceuticals for the listing of various pharmaceuticals
PHARMAC and Pacific Pharmaceuticals Ltd (Pacific) have entered into a provisional agreement for the listing of Pacific’s brand of lamotrigine, and for the continued listing of several existing products supplied by Pacific. Outline of proposal Under this proposal, there would be: § § § the listing of lamotrigine (Logem) at prices and subsidies below those applying to the currently available range of lamotrigine; a price and subsidy increase for betamethasone (Beta Cream and Beta Ointment); and an extension of subsidy protection periods for a number of other pharmaceuticals.
Feedback sought PHARMAC welcomes feedback on this proposal. If you wish to submit feedback on this proposal please submit them in writing by 3 December 2007 to: Sean Dougherty Therapeutic Group Manager PHARMAC PO Box 10-254 Wellington 6143 Email: Sean.Dougherty@pharmac.govt.nz Fax: (04) 460 4995
Details of Proposal § The Logem brand of lamotrigine would be listed in Section B and Part II of Section H of the Pharmaceutical Schedule from 1 June 2008 at the following prices and subsidies (ex-manufacturer, excluding GST):
Formulation Tab dispersible 25 mg Tab dispersible 50 mg Tab dispersible 100 mg Brand Logem Logem Logem Pack size 56 56 56 Price and subsidy $24.23 $41.23 $69.28
Chemical Lamotrigine Lamotrigine Lamotrigine
Logem would be protected from delisting and subsidy reduction until 1 February 2010.
A165440 - T07-107
The price and subsidy of Beta Cream and Beta Ointment would increase to the following levels (ex-manufacturer, excluding GST) from 1 July 2008:
Current price and subsidy $1.70 $1.70 Proposed price and subsidy $2.00 $2.20
Chemical Betamethasone valerate Betamethasone valerate
Formulation Cream 0.1% Ointment 0.1%
Brand Beta Cream Beta Ointment
Pack size 50 g 50 g
Beta Cream and Beta Ointment would be protected from delisting and subsidy reduction until 1 July 2011. Additional subsidy and delisting protection periods would apply to the following products as below:
Formulation Tab 100 mg Tab 300 mg Tab 25 mg Tab 50 mg Tab trimethoprim 80 mg and sulphamethoxazole 400 mg Tab 100 mg Tab long-acting 120 mg Brand Progout Progout Amitrip Amitrip Trisul Doxine Verpamil SR Protection period 1 January 2009 1 January 2009 1 July 2011 1 July 2011 1 July 2011 1 July 2011 1 July 2011
Chemical Allopurinol Allopurinol Amitriptyline Amitriptyline Co-trimoxazole Doxycycline Verapamil
If you have any questions in relation to this proposal, please contact me on (04) 916 7534 or by email: Sean.Dougherty@pharmac.govt.nz. Yours sincerely
Sean Dougherty Therapeutic Group Manager
A165440 - T07-107
PHARMAC and Pacific Pharmaceuticals Ltd (Pacific) have entered into a provisional agreement for the listing of Pacific’s brand of lamotrigine,…
This text has been extracted from the source PDF document.
Also available as plain text.
Please contact webmaster to discuss alternative format options.